Brief: AN2 Provides Strategic Update For Phase 3 Ebo-301 Trial In Treatment Refractory Mac Lung Disease
24/02/2025 13:24
Feb 24 (Reuters) - AN2 Therapeutics Inc ANTX.O :
* AN2 PROVIDES STRATEGIC UPDATE FOR PHASE 3 EBO-301 TRIAL IN
TREATMENT REFRACTORY MAC LUNG DISEASE
* AN2 THERAPEUTICS INC: TO RELEASE TOPLINE PHASE 3 RESULTS
FOR
EBO-301 IN Q2 OF 2025
Source text: ID:nBw9dnrcla
Further company coverage: ANTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview